Efficacy analysis and prognostic factors of first-line chemotherapy combined with immunotherapy in extensive-stage small cell lung cancer: a real-world study

Related articles

1. Benefit of Consolidation Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer Patients Treated with Immunotherapy: Data from Slovenian Cohort

   This article has 9 authors:

   1. Marina Čakš
   2. Urška Janžič
   3. Tjaša Rutar
   4. Mojca Unk
   5. Ana Demšar
   6. Katja Mohorčič
   7. Nina Turnšek
   8. Erika Matos
   9. Jasna But-Hadžić

2. The Prognostic and Predictive Role of ATM Expression in Patients with Metastatic Non-Small Cell Lung Cancer Receiving Pembrolizumab Monotherapy or Combination with Chemotherapy

   This article has 8 authors:

   1. Jamshid Hamdard
   2. Harun Muğlu
   3. Ahmet Bilici
   4. Elif Kuzucular
   5. Özgür Açıkgöz
   6. Ömer Fatih Ölmez
   7. Oktay Olmuşçelik
   8. Özcan Yıldız

3. Autologous Cytokine-Induced Killer (CIK) Cell Immunotherapy plus Sintilimab and Chemotherapy in Advanced Non‒Small-Cell Lung Cancer: 3-Year Outcomes From the Phase Ib CCICC-002a Study

   This article has 20 authors:

   1. Weihong Zhang
   2. Yanping Chen
   3. Li Zhou
   4. Yanjuan Xiong
   5. Fan Yang
   6. Meng Shen
   7. Shuzhan Li
   8. Jiali Zhang
   9. Weijiao Du
   10. Zhenzhen Hui
   11. Xiao Tian
   12. Ying Han
   13. Yang Wang
   14. Shunju Pang
   15. Baozhu Ren
   16. Xinwei Zhang
   17. Shui Cao
   18. Xiubao Ren
   19. Runmei Li
   20. Liang Liu